Comparative Pharmacology
Head-to-head clinical analysis: CARTROL versus TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARTROL versus TIMOLOL MALEATE.
CARTROL vs TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARTROL is a beta-1 selective adrenergic receptor antagonist. It inhibits the effects of catecholamines on beta-1 receptors in the heart, reducing heart rate, myocardial contractility, and blood pressure.
Non-selective beta-adrenergic receptor antagonist (beta-blocker). Competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and cardiac output. Also decreases aqueous humor production in the eye by blocking beta2 receptors on ciliary epithelium.
Adults: 2.5 mg orally twice daily, titrated up to maximum 10 mg twice daily.
Systemic: 1 drop of 0.25% or 0.5% solution in affected eye(s) twice daily. Additional indication: 0.5% gel-forming solution once daily. Oral: 10 mg twice daily, may increase to 20 mg twice daily if needed.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
2-3 hours (terminal); prolonged in hepatic impairment
Primarily renal excretion (approx. 70% unchanged drug), with 20% biliary/fecal, and 10% metabolism to inactive metabolites.
Renal: 20% unchanged; biliary/fecal: 80% as metabolites
Category C
Category A/B
Beta-Blocker
Beta-Blocker